Physician profile
Danille Prime
NPI 1366702847
$26,967.25
in general payments reported to CMS, 2019-2025
25 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.89 · 2021: $64.91 · 2022: $99.00 · 2023: $22K · 2024: $3,480 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,937 · Travel and Lodging: $2,783 · Food and Beverage: $2,738 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,140.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,937.00 |
| Travel and Lodging | $2,782.51 |
| Food and Beverage | $2,737.77 |
| Education | $193.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $21,526.32 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $2,937.00 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $688.08 | 2023-2025 | Breztri, Tezspire, Fasenra |
| Jazz Pharmaceuticals INC. | $266.05 | 2024-2025 | |
| Glaxosmithkline, LLC. | $248.14 | 2023-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.12 | 2022-2025 | |
| Insmed, INC. | $145.19 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $106.86 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $105.54 | 2024-2025 | Zerbaxa |
| Genzyme Corporation | $102.05 | 2025 | |
| Ani Pharmaceuticals, INC. | $86.91 | 2024-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $86.32 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $78.10 | 2024-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Amgen INC. | $58.71 | 2024-2025 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $52.11 | 2021 | |
| Viatris Specialty LLC | $31.38 | 2025 | Yupelri |
| Stryker Corporation | $24.92 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Vifor Pharma, INC. | $21.56 | 2024 | Zemaira |
| Electromed, INC. | $21.54 | 2024 | Smartvest |
| Pfizer INC. | $21.01 | 2024 | |
| Philips North America LLC | $15.56 | 2024 | (Ak6) Vest Therapy |
| Bayer Healthcare Pharmaceuticals INC. | $14.29 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.80 | 2021 | |
| Allergan, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danille Prime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.